Efficacy and Safety of Meropenem–Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis

Advances in Therapy

Volumn 36, Issue 7, 2019, Pages 1771-1777

  Bassetti, Matteo ^a   Giacobbe, Daniele Roberto ^b   Patel, Niki ^c   Tillotson, Glenn ^d   Massey, Jill ^c  

^a Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Melinta Therapeutics Inc   (United States)

^d GST Micro LLC   (United States)

Author keywords

Antimicrobial failure; Antimicrobial resistance; Carbapenem resistance; Enterobacteriaceae; Meropenem vaborbactam; TANGO II

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CARBAPENEMASE; COLISTIN; MEROPENEM; PENICILLINASE; POLYMYXIN B; TIGECYCLINE; VABORBACTAM; ANTIINFECTIVE AGENT; BORONIC ACID DERIVATIVE;

ALL CAUSE MORTALITY; ANTIBIOTIC THERAPY; ARTICLE; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTERIACEAE INFECTION; HUMAN; MONOTHERAPY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; ADULT; DOSE RESPONSE; DRUG EFFECT; FEMALE; MALE; MIDDLE AGED;

ADULT; ANTI-BACTERIAL AGENTS; BORONIC ACIDS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MEROPENEM; MIDDLE AGED;

EID: 85066030517     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-019-00981-y     Document Type: Article

References (12)

1. Alexander EL, Loutit J, Tumbarello M, et al. Carbapenem-resistant Enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials. Open Forum Infect Dis. 2017;4:ofx063.
2. Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39.
3. Giacobbe DR, Maraolo AE, Viscoli C. Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies. Eur J Clin Microbiol Infect Dis. 2017;36:1707–9.
4. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322–8.
5. Bassetti M, Giacobbe DR, Giamarellou H, et al. Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect. 2018;24:133–44.
6. Bassetti M, Righi E, Carnelutti A, Graziano E, Russo A. Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. Expert Rev Anti Infect Ther. 2018;16:749–61.
7. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70:2133–43.
8. Zilberberg MD, Nathanson BH, Sulham K, et al. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis. 2017;17:279.
9. Giacobbe DR, Del Bono V, Trecarichi EM, et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case–control-control study. Clin Microbiol Infect. 2015;21(1106):e1–8.
10. Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem. 2015;58:3682–92.
11. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem–vaborbactam vs piperacillin–tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319:788–99.
12. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7:439–55.